Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation.

diglycerides inflammation lipidomics lipoprotein(a) monocytes

Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
25 Jan 2024
Historique:
medline: 25 1 2024
pubmed: 25 1 2024
entrez: 25 1 2024
Statut: aheadofprint

Résumé

Oxidized phospholipids play a key role in the atherogenic potential of lipoprotein(a; Lp[a]); however, Lp(a) is a complex particle that warrants research into additional proinflammatory mediators. We hypothesized that additional Lp(a)-associated lipids contribute to the atherogenicity of Lp(a). Untargeted lipidomics was performed on plasma and isolated lipoprotein fractions. The atherogenicity of the observed Lp(a)-associated lipids was tested ex vivo in primary human monocytes by RNA sequencing, ELISA, Western blot, and transendothelial migratory assays. Using immunofluorescence staining and single-cell RNA sequencing, the phenotype of macrophages was investigated in human atherosclerotic lesions. Compared with healthy individuals with low/normal Lp(a) levels (median, 7 mg/dL [18 nmol/L]; n=13), individuals with elevated Lp(a) levels (median, 87 mg/dL [218 nmol/L]; n=12) demonstrated an increase in lipid species, particularly diacylglycerols (DGs) and lysophosphatidic acid (LPA). DG and the LPA precursor lysophosphatidylcholine were enriched in the Lp(a) fraction. Ex vivo stimulation with DG(40:6) demonstrated a significant upregulation in proinflammatory pathways related to leukocyte migration, chemotaxis, NF-κB (nuclear factor kappa B) signaling, and cytokine production. Functional assessment showed a dose-dependent increase in the secretion of IL (interleukin)-6, IL-8, and IL-1β after DG(40:6) and DG(38:4) stimulation, which was, in part, mediated via the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome. Conversely, LPA-stimulated monocytes did not exhibit an inflammatory phenotype. Furthermore, activation of monocytes by DGs and LPA increased their transendothelial migratory capacity. Human atherosclerotic plaques from patients with high Lp(a) levels demonstrated colocalization of Lp(a) with M1 macrophages, and an enrichment of CD68 Lp(a)-associated DGs and LPA have a potential role in Lp(a)-induced monocyte inflammation by increasing cytokine secretion and monocyte transendothelial migration. This DG-induced inflammation is, in part, NLRP3 inflammasome dependent.

Sections du résumé

BACKGROUND UNASSIGNED
Oxidized phospholipids play a key role in the atherogenic potential of lipoprotein(a; Lp[a]); however, Lp(a) is a complex particle that warrants research into additional proinflammatory mediators. We hypothesized that additional Lp(a)-associated lipids contribute to the atherogenicity of Lp(a).
METHODS UNASSIGNED
Untargeted lipidomics was performed on plasma and isolated lipoprotein fractions. The atherogenicity of the observed Lp(a)-associated lipids was tested ex vivo in primary human monocytes by RNA sequencing, ELISA, Western blot, and transendothelial migratory assays. Using immunofluorescence staining and single-cell RNA sequencing, the phenotype of macrophages was investigated in human atherosclerotic lesions.
RESULTS UNASSIGNED
Compared with healthy individuals with low/normal Lp(a) levels (median, 7 mg/dL [18 nmol/L]; n=13), individuals with elevated Lp(a) levels (median, 87 mg/dL [218 nmol/L]; n=12) demonstrated an increase in lipid species, particularly diacylglycerols (DGs) and lysophosphatidic acid (LPA). DG and the LPA precursor lysophosphatidylcholine were enriched in the Lp(a) fraction. Ex vivo stimulation with DG(40:6) demonstrated a significant upregulation in proinflammatory pathways related to leukocyte migration, chemotaxis, NF-κB (nuclear factor kappa B) signaling, and cytokine production. Functional assessment showed a dose-dependent increase in the secretion of IL (interleukin)-6, IL-8, and IL-1β after DG(40:6) and DG(38:4) stimulation, which was, in part, mediated via the NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome. Conversely, LPA-stimulated monocytes did not exhibit an inflammatory phenotype. Furthermore, activation of monocytes by DGs and LPA increased their transendothelial migratory capacity. Human atherosclerotic plaques from patients with high Lp(a) levels demonstrated colocalization of Lp(a) with M1 macrophages, and an enrichment of CD68
CONCLUSIONS UNASSIGNED
Lp(a)-associated DGs and LPA have a potential role in Lp(a)-induced monocyte inflammation by increasing cytokine secretion and monocyte transendothelial migration. This DG-induced inflammation is, in part, NLRP3 inflammasome dependent.

Identifiants

pubmed: 38269588
doi: 10.1161/ATVBAHA.123.319937
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Kim E Dzobo (KE)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).
Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.).

Arjen Cupido (A)

Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (A.C., L.C.A.S., E.S.G.S.).

Barend M Mol (BM)

Department of Vascular Surgery, University Medical Centre Utrecht, the Netherlands (B.M.M., D.P.V.d.K.).

Lotte C A Stiekema (LCA)

Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (A.C., L.C.A.S., E.S.G.S.).

Miranda Versloot (M)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).
Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.).

Maaike Winkelmeijer (M)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Jorge Peter (J)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Anne-Marije Pennekamp (AM)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Stefan Havik (S)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Frédéric M Vaz (FM)

Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, the Netherlands. (F.M.V., M.v.W.).

Michel van Weeghel (M)

Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, the Netherlands. (F.M.V., M.v.W.).

Koen H M Prange (KHM)

Department of Medical Biochemistry, Amsterdam Infection and Immunity, Amsterdam UMC, University of Amsterdam, the Netherlands. (K.H.M.P., M.P.J.d.W.).

Johannes H M Levels (JHM)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Menno P J de Winther (MPJ)

Department of Medical Biochemistry, Amsterdam Infection and Immunity, Amsterdam UMC, University of Amsterdam, the Netherlands. (K.H.M.P., M.P.J.d.W.).

Sotirios Tsimikas (S)

Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, La Jolla (S.T.).

Albert K Groen (AK)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).

Erik S G Stroes (ESG)

Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (A.C., L.C.A.S., E.S.G.S.).

Dominique P V de Kleijn (DPV)

Department of Vascular Surgery, University Medical Centre Utrecht, the Netherlands (B.M.M., D.P.V.d.K.).

Jeffrey Kroon (J)

Departments of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, the Netherlands. (K.E.D., M.V., M.W., J.P., A.-M.P., S.H., J.H.M.L., A.K.G., J.K.).
Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, the Netherlands (K.E.D., M.V., J.K.).
Laboratory of Angiogenesis and Vascular Metabolism, VIB-KU Leuven Center for Cancer Biology, VIB, Belgium (J.K.).
Laboratory of Angiogenesis and Vascular Metabolism, Department of Oncology, KU Leuven and Leuven Cancer Institute, Belgium (J.K.).

Classifications MeSH